Case Report on Leiomyosarcoma of the Vulva:  A Rare Pathology by Smith, Samantha A et al.
Volume 6 Issue 3 Article 6 
2020 
Case Report on Leiomyosarcoma of the Vulva: A Rare Pathology 
Samantha A. Smith, Nadim Bou Zgheib, Andrea M. Vallejos, and Jonathan D. Cuda 
Author Affiliations 
Samantha A. Smith (Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia) 
Nadim Bou Zgheib (Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia) 
Andrea M. Vallejos (Valley Health Systems OB/GYN, Huntington, West Virginia) 
Jonathan D. Cuda (Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia) 
Corresponding Author 
Samantha A. Smith 
Marshall University Joan C. Edwards School of Medicine 
Huntington, West Virginia 
Email: smith2028@marshall.edu 
Follow this and additional works at: https://mds.marshall.edu/mjm 
 Part of the Medical Pathology Commons, Obstetrics and Gynecology Commons, and the Oncology 
Commons 
This work is licensed under a Creative Commons Attribution 4.0 License. 
Recommended Citation 
Smith, Samantha A.; Bou Zgheib, Nadim; Vallejos, Andrea M.; and Cuda, Jonathan D. (2020) "Case Report on 
Leiomyosarcoma of the Vulva: A Rare Pathology," Marshall Journal of Medicine: Vol. 6: Iss. 3, Article 6. 
DOI: 10.33470/2379-9536.1294 
Available at: https://mds.marshall.edu/mjm/vol6/iss3/6 
DOI: 10.33470/2379-9536.1294 








Leiomyosarcoma (LMS) of the vulva is rare. However it is the most common histologic subtype 
of vulvar sarcoma, accounting for approximately 1% of all vulvar malignancies.1-8 Whether 
genetics and epigenetics play a role in pathogenesis is unclear.1  The tumor is slow-growing with 
non-specific symptoms, has high metastatic potential, and follows a bimodal age distribution.1-8  
Diagnosis and prognosis are based upon immunohistochemical expression and criteria from early 
literature.1,3,5-7  The most common therapeutic approach involves radical vulvectomy with lymph 
node resection. The value of adjuvant chemotherapy and radiation remains unknown.1,3,5-8 Our 









Sarcomas of the vulva are relatively rare, accounting for only 1-3% of all vulvar malignancies.1-8  
They are of mesenchymal origin and constitute a vast array of histologic subtypes.1,5  Reported 
histologic variants include leiomyosarcoma, rhabdomyosarcoma, liposarcoma, angiosarcoma, 
malignant peripheral nerve sheath tumor, malignant fibrous histiocytoma, and epithelioid 
sarcoma.1,3,6   
 
Of the above, leiomyosarcoma (LMS) is the most common sarcoma subtype to involve the vulva.  
It follows a bimodal age distribution with an average age of 30-40 years old.  The first mode 
represents ages 20-30.1,3,5,6 Cases within this age group are becoming increasingly prevalent, and 
whether this has any correlation with reproductive hormones is in question.1,5 The second mode 
affects a more elderly population.1,2,8   
 
The tumor is slow-growing with non-specific symptoms and has high metastatic potential.2,3,8  
Tumors may originate from the smooth muscle of blood vessels, tissue of the round ligament, 
myoepithelium of Bartholin glands, or arrector-pili muscles.1,3,5   Pathogenesis related to genetic 
predisposition and lifestyle are speculative due to the prevalence of LMS in western countries.1   
The following case describes a 46-year-old female with LMS of the left labia.  The rarity of LMS 





Our case is a 46-year-old Caucasian female, gravida 2, para 2, who presented with a painless 
mass of the left labia majora situated between the left Bartholin gland area and the posterior 
fourchette and measuring around three cm with a solid consistency. The patient's medical history 
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included menarche at age ten and menopause at age 39 following a partial hysterectomy for 
menorrhagia. Family history included primary relatives with breast cancer and melanoma.  
Several distant relatives were also diagnosed with breast cancer, cervical cancer, and prostate 
cancer.  Genetic testing for the presence of alterations in 67 different cancer predisposition genes 
associated with hereditary cancer syndromes only revealed a variant of unknown significance, 
despite her extensive family history of cancer.  She denied any history of smoking or previous 
contact with hazardous materials.   
 
She underwent an excisional procedure of her left vulvar mass measuring a 3 x 2.5 cm with a 
solid consistency.  The pathology showed a mitotically active malignant spindle cell neoplasm 
with smooth muscle actin and desmin expression (Figures 1-3). Tumor cells were negative for 
cytokeratin AE1/AE3, p40, S100, myogenin, myo-D1, caldesmon, CD34, STAT-6, and TLE1. 
The histologic findings in conjunction with the immunohistochemical profile supported a 
diagnosis of leiomyosarcoma with positive margins.  
 
Following the initial excision, a PET-CT scan revealed no evidence of metastatic disease or 
pulmonary nodules.  Uptake was only present at the level of the labia.  Further surgery was 
indicated to excise the residual disease. A left partial radical vulvectomy was performed and the 
vulvar scar was removed with 1-2 cm of margin down to the endopelvic fascia.  No evidence of 
macroscopic disease was noted.  However, the pathology revealed few foci of residual 
leiomyosarcoma associated with procedural scar and persistently positive margins. The final 
pathology was consistent with FIGO stage 1B vulvar leiomyosarcoma. 
 
She was given eight weeks to recover from this procedure and then underwent a third surgical 
procedure which included examination under anesthesia, bilateral inguinofemoral lymph node 
dissection, and posterior radical vulvectomy. Specimens obtained included bilateral 
inguinofemoral lymph nodes and a radical excision of the posterior vulva and scar with 1-2 cm 
margins down to endopelvic fascia.  No macroscopic evidence of inguinofemoral lymph node 
involvement was noted during the operation.  Pathology revealed a focus of residual 
leiomyosarcoma with negative margins and no evidence of regional lymph node disease. The 
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Figure 2. Tumor cells demonstrate moderate cytologic atypia in this high power field. Arrows 
mark three mitotic figures (400x magnification). 
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Onset of vulvar LMS is often insidious. It may arise from an existing leiomyoma, but most are 
de novo.8   LMS presents clinically as a painless, asymptomatic mass in early stages.  The mass is 
solid, ranging between 1.5 to 16 cm, and may precipitate pain, bleeding, and voiding difficulty 
with increased infiltration and size.1,3,5,6  The most common localization is the labia majora, 
followed by Bartholin gland, clitoris, and labia minora.3,5,6,7,8] Due to the clinical presentation, 
LMS is often mistaken for a more benign pathology: Bartholin gland cyst, leiomyoma, lipoma, 
fibroma, infectious granuloma, or myoma.2,3,5,6,7 Misdiagnosis delays treatment and may provide 
potential for metastatic spread, so considering LMS is always important.1,3,6,7 
 
Diagnosis of LMS requires at least three of four criteria, according to Nielsen et al.: (1) 
infiltrative margins, (2) diameter >/= 5 cm, (3) moderate-to-severe (grade 2 or 3) cytologic 
atypia, or (4) >/= 5 mitotic figures per 10 high-power fields.1,3,5-7 Patients with one or two of the 
above criteria meet the diagnoses of leiomyoma and atypical leiomyoma, respectively.3,6,7   
Recent evidence suggests uterine criteria for LMS is equally sensitive and more specific for 
classifying vulvovaginal smooth muscle tumors according to patient outcome.9 In this study, 
tumor necrosis was also assessed as a valuable feature for determining malignant potential.  
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Prognostication is based on mitotic activity, tumor size and grade, pattern of tumor interface, 
necrosis, and metastatic spread.1,3,6,8,9 
 
Muscle immunohistochemical markers such as desmin and actin are expressed in LMS, as 
exhibited by our patient case. Other markers which may be expressed include HHF-35, 
caldesmon, and estrogen receptor (ER). Ki-67 proliferation index is often elevated.  
Primary therapeutic recommendation is complete surgical excision of the lesion with negative 
margins, although there is no consensus on surgical approach.1,3,5-8 The most common approach 
involves radical vulvectomy with occasional lymph node resection, which was performed in this 
case.3 The value of lymphadenectomy in vulvar leiomyosarcoma remains questionable and there 
is no data supporting the routine performance of lymphadenectomy in these cases.   
 
Some case reports state that low-grade tumors may require only wide local excision of the lesion 
with negative margins.3,5 Other cases describe the importance of radiation following radical 
vulvectomy for tumors > 5 cm.3,5,6 Additional measures may include radiation or chemotherapy 
at the discretion of the oncologist. Necessity of adjuvant therapy is unknown at this time, 
although it may decrease risk of relapse and further metastatic spread.3,5,7 Recurrence and 




Leiomyosarcoma (LMS) is rare and insidious. Incorporating this pathology into a differential 
diagnosis is key when evaluating subcutaneous vulvar lesions. Established diagnostic criteria and 
immunohistochemical stains aid in proper identification. Early surgical excision with negative 
margins and close follow-up decreases but does not eliminate risk of metastasis and recurrence 
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